

NOGGO
e.v.

Nord-Ostdeutsche Gesellschaft
für Gynäkologische Onkologie e.V.



Endorsed by ENGOT

ENGOT
+

EUROPEAN NETWORK
OF GYNECOLOGICAL
ONCOLOGICAL TRIAL GROUPS



Global Gynecologic Oncology Hub

Translational Research, Early Discovery,
and the Shaping of Future Policy



**Together,
we're not just attending a conference
We're launching a movement.**

Palace of Parliament,
Bucharest, Romania
March 26-28, 2026


Final overall survival analysis among patients with FRα-positive, platinum-resistant ovarian cancer (PROC) treated with mirvetuximab soravtansine (MIRV) vs investigator's choice chemotherapy (ICC) in the phase 3 MIRASOL (GOG 3045/ENGOT-ov55) study**

Final Overall Survival^a

At the final analysis, the HR for OS was 0.68 for MIRV vs ICC, with patients treated with MIRV exhibiting a **32% reduction in risk of death**

	Final analysis ^a 30.5-mo follow-up		Primary analysis ^b 13.1-mo follow-up	
	MIRV (n=227)	ICC (n=226)	MIRV (n=227)	ICC (n=226)
mOS (95% CI)	16.85 (14.36-19.78)	13.34 (11.37-15.15)	16.46 (14.46-24.57)	12.75 (10.91-14.36)
HR (95% CI)	0.68 (0.54-0.84)		0.67 (0.50-0.89)	
P value	0.0004*		0.0046	

*OS reached statistical significance in primary analysis. The P value at the final analysis is descriptive.



HR, hazard ratio; ICC, investigator's choice chemotherapy; ITT, intent-to-treat; MIRV, mirvetuximab soravtansine; OS, overall survival; PFS, progression-free survival.

^aData cutoff: September 26, 2024; Van Gorp T, et al. Abstract 939696 2025 SGO Annual Meeting, March 14-17, 2025, Seattle, WA, USA.

^bData cutoff: March 6, 2023; Moore KN, et al. N Engl J Med. 2023;389(23):2162-2174.

**The data from the final analysis is not included in SmPC.

Medicinal product subject to restricted medical prescription: PR
Scientific material intended for healthcare professionals.
The reporting of suspected adverse reactions for Abbvie products can be done to the National Agency of Medicines and Medical Devices in Romania (ANMDDMR), to the e-mail address adr@anm.ro or to AbbVie Romania SRL, Pharmacovigilance Department - Phone: +40215293429 / E-mail: farmacovigilenta_romania@abbvie.com

Please refer to SmPC for additional information. (Scan QR code)



QR code Mirvetuximab soravtansine, EMA Summary of Product Characteristics

abbvie

ABBVIE S.R.L.
Lake View, Strada Barbu Văcărescu nr. 301-311, etaj 2,
sector 2, C.P. 020276, București, România
Tel: +4 021 529 3035 / Fax: +4 021 529 3031

MIRV-RO-00003-E/ Creation Date: Feb 2026

General information

Dates

26th – 28th March 2026


Venue

Palace of the Parliament


Strada Izvor 2-4, Bucharest, 050563, Romania

Access to the Palace of Parliament through Gate C1 (or Entrance C1) is the main entrance for conference participants.


The gate is located on the side of the building facing United Nations Boulevard and is accessible by crossing Izvor Park.



Venue layout



Exhibition area - C6



Logistic organizer



Romania Travel Plus SRL
Mihaela Agaficioaie
mihaela.agaficioaie@rotravelplus.com

www.rotravelplus.com

Official language

English is the official language of the event. No simultaneous translations will be provided.

Badges

You will not be permitted to enter the event area without your badges.

CME Accreditation

The event is accredited by the Romanian College of Physicians.

Participating delegates will receive a Certificate with CME Credits based on personal attendance to the sessions.



The Palace of the Parliament, located in the historic center of Bucharest, is one of the largest and most impressive administrative buildings in the world. Surrounded by the Izvor and Unirii parks, it offers multiple grand halls and modern conference facilities, suitable for large-scale international congresses. The venue is easily accessible from all parts of the city and within 30 minutes from Henri Coandă International Airport.



Organizers

North Eastern German Society for
Gynecologic Oncology (NOGGO)

ARCOF

Conference Chairs Scientific Board

Elena Ioana Braicu

Dana Lucia Stanculeanu

Gheorghe Peltecu

Jalid Sehoul

Invited speakers


Andrei Baci Romania 	Michael Birrer USA 	Elena Ioana Braicu Germany 	Dana-Lucia Stanculeanu Romania 
James Brenton UK 	George Calin USA 	Nicoletta Colombo Italy 	Robert Coleman USA 
Mihaela Cristea USA 	Oliver Dorigo USA 	Mihnea Dragomir Germany 	Adelina Silvana Gheorghe Romania 
Gottfried Konecny USA 	Jonathan Ledermann UK 	Sven Mahner Germany 	Frederik Marmé Germany 
Daniela Matei USA 	Delia Mezzananza Italy 	Sevda Memet Romania 	Shibani Nicum UK 
Cornelia Nitipir Bucharest, Romania 	Catalina Poiana Bucharest, Romania 	Jalid Sehoul Germany 	Dennis Slamon USA 
Constantin Volovat Iasi, Romania 	Octav Ginghina Bucharest, Romania 	Claudia Burz Cluj, Romania 	Dan Eniu Cluj, Romania 
Octavian Andronic Bucharest, Romania 	Radu Vidra Cluj, Romania 	Marcela Carausu Bucharest, Romania 	Vlad Croitoru Bucharest, Romania 
Paul Kubelac Cluj, Romania 	Radu Matei Bucharest, Romania 	Razvan Negreanu Bucharest, Romania 	Eliza Maria Armeanu Iasi, Romania 
Amir Hubeishie Timisoara, Romania 	Cristina Lungulescu-Berisha Craiova, Romania 	Stefania Toma Bucharest, Romania 	Isabela Komporaly Bucharest, Romania 
ELENA IOVANESCU Romania 			

Scientific committee


Elena-Ioana Braicu

 Germany


Ioana Berindan Neagoe

 Romania


Alexandru Blidaru

 Romania


Mircea Dediu

 Romania


Gabriel Dimofte

 Romania


Adelina Silvana Gheorghe

 Romania


Dan Jinga

 Romania


Dragos Median

 Romania

Dana Lucia Stanculeanu

 Romania

Oana Trifanescu

 Romania

- 09:00 - 09:15** **Welcome and Opening Remarks**
Viorel Jinga, Cătălina Poiana, Dana Lucia Stanculeanu, Elena-Ioana Braicu, Jalid Sehouli, Gheorghe Peltecu
- 09:15 - 10:25** **Translational Research: From Concept to Clinical Application**
Chairs: Ioana Berindan Neagoe, Delia Mezzanzanica
- 09:15 - 09:35 The Role of microRNAs in Cancer Development and Therapeutic Targeting
George Calin
- 09:35 - 10:00 Microenvironmental Changes as Therapeutic Targets in Early Ovarian Cancer Genesis
Mihnea Dragomir
- 10:00 - 10:10 Discussion
- 10:10 - 10:25 Ewo Pharma Symposium: Second-Line Options Expand Beyond Chemotherapy in Endometrial Cancer
Dana Stanculeanu
- 10:25 - 10:45** **Coffee Break & Industry Exhibition**
- 10:45 - 12:45** **Liquid Biopsies: From Research Tool to Clinical Decision-Making**
Chairs: Delia Mezzanzanica, Irina Cazacu-Croitoru
- 10:45 - 11:05 Circulating Tumor DNA: Clinical Validation and Implementation
Victor Velculescu
- 11:05 - 11:25 Transcriptional Changes Associated with Tumor Presence Detected in Liquid Biopsy
Ioana Berindan Neagoe
- 11:25 - 11:45 Translating Liquid Biopsy into Real-World Clinical Decisions
Adelina Silvana Gheorghe
- 11:45 - 12:00 Discussion
- 12:00 - 12:45 MSD Symposium Cervical Cancer Across the Care Continuum: From Prevention to Treatment
Dana Lucia Stanculeanu, Gheorghe Peltecu, Serban Nastasia
- 12:45 - 13:30** **Lunch Break**

- 13:30 - 15:15 Drug Development Journeys: Phase I to Market**
Chairs: Elena-Ioana Braicu, Dan Jinga, Dana-Lucia Stanculeanu
- 13:30 - 13:50 PARP Inhibitors: From First-in-Human Studies to Pan-Gynecologic Applications
Jonathan Ledermann
- 13:50 - 14:10 Bevacizumab Across Gynecologic Cancers: From Phase I to Standard of Care
Nicoletta Colombo
- 14:10 - 14:30 Checkpoint Inhibitors: Phase I Discoveries to Gynecologic Oncology Approvals
Phillipp Harter
- 14:30 - 14:45 Discussion
- 14:45 - 15:00 Pharma& symposium - New horizons in PARPi for patients with Advanced Ovarian Cancer
Elena-Ioana Braicu
- 15:00 - 15:15 Stada Symposium - Bone Health Matters: Optimizing the Management of Bone Metastases with Zvogra (denosumab)
Dragos Median
- 15:15 - 15:25 Coffee Break & Industry Exhibition**
- 15:25 - 16:35 Biomarker Development and Cross-Sector Learning**
Chairs: Dragos Median, Mircea Dediu
- 15:25 - 15:45 Are Biomarkers Valid or Is Our Approach Incorrect? The HER2 vs. FRA Story
Delia Mezzanzanica
- 15:45 - 16:05 HRD Testing: From Discovery to Clinical Implementation
Daniela Zob
- 16:05 - 16:25 HER2-Targeted Therapy: Lessons from Breast Cancer for Gynecologic Oncology
Dennis Slamon
- 16:25 - 16:40 Discussion
- 16:35 - 18:05 Industry-Sponsored Symposium**
- 16:35 - 16:55 BMS Symposium - Medical Hub
Where Legacy Meets Innovation: From Classic Biomarkers to New Therapeutic Mechanisms in TNBC
Mircea Dediu
- 16:55 - 17:35 BMS Symposium- Medical Hub
Biomarkers Testing Across Pathologies: From Diagnosis to Treatment Decisions
Dana Lucia Stanculeanu, Claudia Burz
- 17:35 - 18:05 *Gilead Symposium: Bridging guidelines and practice: Expert consensus on mTNBC and HR+/HER2—in Romania*
Dragos Median
- 18:05 - 18:15 Day 1 Summary and Key Insights**

March 26, Courses for Young Researchers NICOLAE BĂLCESCU HALL

- 10:00 - 11:00** **Leadership for doctors:
From Resident to Leader - dealing with difficult personalities (DISC)**
Moderator: Marinela Tănase
Format: Semi-interactive (reflection + micro-skills)
- 12:45 - 13:30** **Lunch Break**
- 13:00 - 15:20** **Course A: Translational Research Integration - From Bench to Bedside**
Moderators: Adelina Silvana Gheorghe, Delia Mezzanzanica, Irina Cazacu-Croitoru
Format: Interactive workshop with case studies
- 13:00-13:20 How to Shift from Clinical to Translational Research? A Practical Roadmap from Clinic to Lab
Adelina Silvana Gheorghe
- 13:20-13:40 From Bench to Bedside: Designing Clinically Relevant Translational Studies
Marcela Cărăușu
- 13:40-14:00 From Biomarker Discovery to Clinical Application
Bogdan Georgescu
- 14:00-14:20 Integrating Clinical Data with Multi-Omics for Translational Cancer Research
Delia Mezzanzanica
- 14:20-14:50 Panel Discussion and Networking: Skills for a Translational Research Career
Panel of Experts
- 14:50 - 15:20 Patient Journey Mapping: Ovarian Cancer
Adelina Silvana Gheorghe

- 08:45 - 09:10** **Welcome address by the Minister of Health and overview of Romania's cancer care initiatives**
- 09:00 - 10:25** **Understanding and Overcoming Resistance**
Chairs: Cornelia Nitipir, Gabriel Kacso
- 09:00 - 09:20 Years of Insights into Platinum-Based Resistance: From Discovery to Clinical Management
James Brenton
- 09:20 - 09:40 PARP Inhibitor Resistance: Laboratory Discovery to Clinical Solutions
Daniela Matei
- 09:40 - 09:55 Discussion
- 09:55 - 10:25 Eli Lilly Symposium: What Does Platinum Sensitivity Mean After PARP Inhibitors in Ovarian Cancer?
Elena Ioana Braicu
- 10:25- 10:40** **Coffee Break & Industry Exhibition**
- 10:40 - 10:55** **Translating Health Science for the Public**
Daniel Nagel
- 10:55 - 12:35** **Industry-Sponsored Symposium**
- 10:55 - 11:55 Educational session organized with the support of Abbvie - Redefining Possibilities: Mirvetuximab Soravtansine and the PROC challenge
Jalid Sehouli, Mihnea Dragomir, Constantin Volovat, E. Ioana Braicu, Dana Stanculeanu, Dragos Median
- 11:55 - 12:35 AstraZeneca Symposium: Endometrial Cancer Treatment in the Molecular Era
Nicoletta Colombo, Elena Ioana Braicu
- 12:35 - 13:10** **Lunch Break**
- 13:10- 14:10** **Conferral Ceremony of the Title Doctor Honoris Causa of the Carol Davila University of Medicine and Pharmacy to Prof. Dr. Dennis Slamon**
Prof. Dr. Viorel Jinga - Rector of the Carol Davila Medical University Bucharest

14:10 - 15:40

Next-Generation Therapeutics

Chairs: Gottfried Koneczny, Dana-Lucia Stanculeanu, Mircea Dediu

14:10 - 14:30

CAR-T Therapy for Solid Tumors: Early Phase Progress?

Oliver Dorigo

14:30 - 14:50

Bispecific Antibodies: Principles, Targets and Limitations

Frederik Marmé

14:50 - 15:10

AI-Designed Therapeutics: Predicting Patient Response

Christiane Hoepfer

15:10 - 15:30

Diversity in Early Clinical Trials: Patient Perspectives

Jalid Sehouli

15:30 - 15:40

Discussion

15:40 - 15:50

Coffee Break

15:50 - 16:50

Industry Symposium

AstraZeneca Symposium: Bridging Evidence and Practice in Breast Cancer. Connecting the dots to redefine clinical impact

Dana Lucia Stanculeanu, Cornelia Nitipir, Dragos Median

16:50 - 18:25

Treatment Optimization and Patient-Centered Care

Chairs: Michael Birrer, Radu Vidra

16:50 - 17:10

Optimizing Treatment Sequences in Endometrial Cancer

Michael Birrer

17:10 - 17:30

Optimizing Treatment Sequences in Ovarian Cancer

Robert Coleman

17:30 - 17:50

Mismatch Repair Alterations in Gynecologic Cancers: When Does It Change Clinical Management?

Radu Vidra

17:50 - 18:10

Merck Symposium: Fertility preservation for medical reasons

Cezara Bucur

18:10 - 18:25

REGENERON | MEDISON Symposium: Quality of Life and Survival in Recurrent or Metastatic Cervical Cancer: Insights from EMPOWER Cervical 1

Dragos Median

March 27, Courses for Young Researchers

NICOLAE BĂLCESCU HALL

11:00 - 12:40 Course B: Clinical Trial Design Innovation with PRO Integration

Moderators: Isabela Komporaly, Paul Kubelac, Gottfried Konecny

Format: Hands-on workshop with real trial design exercises

- | | |
|-------------|--|
| 11:00-11:20 | Welcome and Introduction: The Future of Clinical Trial Design
Paul Kubelac |
| 11:20-11:40 | How to read a trial paper: PFS, OS, HR, subgroup traps?
Radu Matei |
| 11:40-12:00 | Integrating Patient-Reported Outcomes (PROs) into Oncology Trials
Vlad Croitoru |
| 12:00-12:30 | Common Mistakes in Clinical Trial Design – And How to Fix Them Before Submission
Gottfried Konecny |
| 12:30-12:40 | Wrap-up and Key Takeaways |

12:35 - 13:10 Lunch Break**13:30 - 15:30 Course C: Building Your Career in Gynecologic Oncology Research**

Moderators: Robert Coleman, Elena Iovanescu, Ștefania Toma

Format: Panel discussion with career mentoring breakout sessions

- | | |
|---------------|--|
| 13:30 - 14:00 | Gynecologic Research: Statistics made easy + figures & tables that convince
Robert Coleman |
| 14:00 - 14:20 | Strategic Career Planning: From Clinical Practice to Research-Driven Careers in Gynecological Oncology
Razvan Negreanu |
| 14:20 - 14:40 | The AI Survival Kit for Young Investigators
Elena Iovanescu |
| 14:40 - 15:00 | Sustainable Excellence: Preventing Burnout and Building Resilient Oncology Careers
Adak Pirmorady-Sehoul |
| 15:00 - 15:30 | Patient Journey Mapping: Endometrial Cancer
Elena Iovănescu |

08:30 - 09:45 Antibody-Drug Conjugates: From Design to Clinical Success

Chairs: Sven Mahner, Daniela Zob, Claudia Burz

08:30 - 08:50 ADC Design Principles: From Biomarker Identification to Payload Selection
Gottfried Konecny

08:50 - 09:10 Mechanisms of Resistance to ADCs: Laboratory Insights to Clinical Management?
Toon Van Gorp

09:10 - 09:30 ADC Combination Strategies: Rational Design and Clinical Implementation
Nicum Shibani

09:30 - 09:45 Discussion

09:45 - 10:30 Industry-Sponsored Symposium

Tubulis Symposium: Novel linkers to unlock the therapeutic potential of ADCs in ovarian cancer and beyond **Jonas Helma-Smets**

10:30 - 11:00 Coffee Break & Industry Exhibition

11:00 - 12:30 Surgery vs. chemotherapy. When to Cut, When to Treat, and When to Turn Up the Heat

Chair: Alexandru Blidaru, Gabriel Dimofte

11:00 - 11:20 Beyond the OR: Pitfalls and Successes in Surgical Trials? Insights from LION & TRUST.
Sven Mahner

11:20 - 11:40 HIPEC vs. Alternatives: IP Chemo, PIPAC, or Systemic-Only?
Octav Ginghina

11:40 - 12:00 TRUST results implementation in Romania
Dan Eniu

12:00 - 12:20 Role of Surgery in Relapsed Ovarian Cancer
Gheorghe Peltecu

12:20 - 12:30 Discussion

12:30 - 13:10 Lunch Break

13:10 - 14:45 **Establishing the Global Gynecologic Oncology Innovation Hub**

13:10 - 13:30 Clinical Trials in Romania: Building Regional Hub Capacity
Volovat Constantin

13:30 - 13:50 Eastern Europe as an Innovation Hub for Clinical Trials: Opportunities and Challenges
Benjamin Willan

13:50 - 14:10 Delivering Excellence in Clinical Trials: Romania's Oncology Enrollment Success – An Industry Perspective
Alina Codrescu

14:10 - 14:30 Bridging Clinical Research: From Academic Oncology to Industry and Vice Versa
Mihaela Cristea

14:30 - 14:45 Panel Discussion and Audience Q&A

14:45 - 15:15 **Industry-Sponsored Symposium**

14:45 - 15:00 Industry Symposium Pfizer: Comparative Real-World Evidence on CDK4/6 Inhibitors: Insights From the P VERIFY Study on OS and rwPFS data
Dana Lucia Stanculeanu

15:00 - 15:15 Pfizer Symposium: IBRANCE in Routine Practice: Updated Insights from IOB
Oana Trifanescu

15:15 - 15:30 **Coffee Break & Industry Exhibition****15:30 - 16:05** **Industry-Sponsored Symposium**

15:30 - 15:50 Industry Symposium Baxter: Optimizing Treatment with Liposomal Doxorubicin: Lessons from Ovarian and Breast Cancer Cases
Adelina Gheorghe

15:50 - 16:05 Industry Symposium Amgen: When Tumors Seem Immunologically Silent, Innovation Emerges: DLL3-Directed Bispecific Therapy
Mircea Dediu

16:05 - 17:05 **Roundtable Discussion: Launching the Global Gynecologic Oncology Innovation Hub**

Moderators Adelina Gheorghe, Elena Iovanescu, Elena Ioana Braicu

Panelists : **Sevda Memet** (MD- MBA- MPP- Stanford University), **Mihaela Cristea** (Clinical Professor - Division of Hematology Oncology - University of California - Irvine), **Andrei Baciu** (Romanian Parliament), **Jalid Sehoul** (Charité), **George Calin** (MD Anderson USA), **Octavian Andronic** (University of Medicine and Pharmacy "Carol Davila" Bucharest)

17:05 - 17:30 **Closing Remarks**

Jalid Sehoul, Dana-Lucia Stanculeanu, Elena-Ioana Braicu

March 28, Courses for Young Researchers

NICOLAE BĂLCESCU HALL

09:00 - 12:30 **Course D: Abstract to Publication: The Fast Track to Publishing**

Chairs: Eliza Armeanu, Octavian Andronic, Nicoletta Colombo

- 09:00-09:20 Inside the Editor's Mind: what journals want + why papers get desk-rejected
Paul Kubelac
- 09:20-09:40 Abstract That Sells: write a clear, structured abstract (from title to conclusion)
Eliza Armeanu
- 09:40-10:00 Beyond Writing: Strategic Journal Targeting and Smart Submission
Octavian Andronic
- 10:00-10:20 Survive Peer Review: how to respond to reviewers + revision strategy
Cristina Lungulescu-Berisha
- 10:20 - 10:50 Patient Journey Mapping: Cervical Cancer
Radu Matei

11:00 - 12:30 **Poster Session**

Moderators: Amir Hubeishie, Elena Iovănescu

12:30 - 13:10 **Lunch Break**

13:30 - 14:30 **OncoNext** The official grand opening of the ARCOF Student Oncology Circle "Shaping tomorrow's oncology leaders"




Empowering precision: Testing algorithm in endometrial cancer

Integrating molecular classification into risk stratification for endometrial cancer


An important advancement in diagnosing and treating endometrial cancers has been the development of molecular classification systems. In 2013, TCGA introduced an endometrial cancer molecular classification system with four subgroups: *POLE* ultramutated, MSI hypermutated, copy-number low, and copy-number high.¹⁻³ The ProMisE classification system, which is based upon the TCGA system, categorizes endometrial cancers into four molecular subtypes: *POLE* mutated, dMMR/MSI-H, p53 abnormal, and NSMP.^{1,3-7}

Molecular classification and risk stratification using the ProMisE criteria

ProMisE algorithm⁵⁻⁷




Disease-specific survival by ProMisE molecular subgroup⁷



In routine clinical practice, molecular classification follows a WHO-endorsed algorithm that first assesses *POLE* mutation status, followed by MMR status and the p53 status:⁸

WHO and ESGO-endorsed pragmatic approach to molecular classification of endometrial cancer in clinical practice⁸



Endometrial cancer classification systems have evolved substantially over the past decade. The incorporation of molecular subgroups into existing risk stratification models affords substantially improved prediction of prognosis for patients. Recently, the FIGO 2023 endometrial cancer staging system has integrated histologic evaluation and molecular classification.^{3,9}

ESGO-ESTRO-ESP 2021 guidelines include endometrial cancer prognostic risk groups incorporating FIGO staging and molecular classification^{†8}

Low risk	<ul style="list-style-type: none"> • Stage I–II POLE mutant no residual disease • Stage IA dMMR or NSMP endometrioid, low-grade, with negative or focal LVSI
Intermediate risk	<ul style="list-style-type: none"> • Stage IB, dMMR or NSMP endometrioid, low-grade, with negative or focal LVSI • Stage IA, dMMR or NSMP endometrioid, high-grade, with negative or focal LVSI • Stage IA, p53 abnormal, or non-endometrioid (serous, clear cell, undifferentiated carcinoma, carcinosarcoma, or mixed), or any combination thereof, without myometrial invasion
High-intermediate risk	<ul style="list-style-type: none"> • Stage I, dMMR or NSMP endometrioid with substantial LVSI, regardless of grade or depth of invasion • Stage IB, dMMR or NSMP endometrioid high-grade, regardless of LVSI • Stage II, dMMR or NSMP endometrioid
High risk	<ul style="list-style-type: none"> • Stage III–IVA, dMMR or NSMP endometrioid, with no residual disease • Stage I–IVA, dMMR or NSMP undifferentiated carcinoma, or carcinosarcoma, with myometrial invasion and no residual disease • Stage I–IVA, p53 abnormal with myometrial invasion and no residual disease
Advanced/metastatic	<ul style="list-style-type: none"> • Stage III–IVA with residual disease of any molecular type • Stage IVB of any molecular type

Comparison of biomarker definitions in common endometrial cancer molecular classification systems

TCGA ³	ProMisE ⁷	Trans-PORTEC ¹⁰
POLE ultramutated	POLE EDM	POLE mutant
MSI hypermutated	dMMR	MSI
Copy-number low	p53 wildtype	NSMP
Copy-number high	p53 abnormal	p53 mutant

*The performance of a complete molecular classification surrogate (POLE mutant, dMMR, NSMP, p53 abnormal) is encouraged in all cases of endometrial cancer for prognostic risk-group stratification and as potential influencing factors for adjuvant and systemic treatment decisions. In early endometrial cancer, the presence of pathogenic POLE mutations or of p53 abnormalities now modify the FIGO stage. Advanced endometrial cancer stage based on surgical and/or clinicopathologic features is not altered after additional molecular characterization, although more prognostic information and treatment directions are obtained by knowledge of the molecular classification.⁹

†For Stage III–IVA POLE mutant endometrial cancer and Stage I–IVA dMMR or NSMP clear cell carcinoma with myometrial invasion, insufficient data are available to allocate these patients to a prognostic risk group in the molecular classification. Prospective registries are recommended.⁸

abn, abnormal; CI, confidence interval; dMMR, deficient mismatch repair; EDM, exonuclease domain mutation; ESGO, European Society of Gynaecological Oncology; ESP, European Society of Pathology; ESTRO, European Society for Radiotherapy and Oncology; FIGO, International Federation of Gynaecology and Obstetrics; HR, hazard ratio; LVSI, lymph–vascular space invasion; MMR, mismatch repair; MSI, microsatellite instability; MSI-H, microsatellite instability/high; MSS, microsatellite stability; NSMP, no specific molecular profile; pMMR, mismatch repair proficient; ProMisE, The Proactive Molecular Risk Classifier for Endometrial Cancer; TCGA, The Cancer Genome Atlas; WHO, World Health Organization.

Referințe: 1. Zheng W, et al. *Cancers (Basel)* 2023;15:4101; 2. Kasiu JC, et al. *Cancers (Basel)* 2021;13:5848; 3. Kandath C, et al. *Nature* 2013;497:67–73; 4. Corr B, et al. *BMJ Med* 2022;1:e000152; 5. Talhouk A, et al. *Br J Cancer* 2015;113: 299–310; 6. Talhouk A, et al. *Cancer* 2017;123:802–813; 7. Kommos S, et al. *Ann Oncol* 2018;29:1180–1888; 8. Crosbie E, et al. *Lancet* 2022;399:1412–1428; 9. Berek JS, et al. *Int J Gynaecol Obstet* 2023;162:383–394; 10. Stelloo E, et al. *Mod Pathol* 2015;28:836–844.

Our Mission and Vision

pharma& aspires to breathe new life into proven medicines. The Company is dedicated to preserving the availability and fostering the further development of essential medicines worldwide to leave no patient behind.

Global Organization with a Broad Reach

pharmaand GmbH (pharma&), part of the pharma& Group, is a privately owned global organization founded in 2017



We are headquartered in Vienna, Austria ...




... comprised of ~400 experienced industry experts ...



... and have a global reach with a geographic focus on Europe and U.S.

Specialty Medicines Across Multiple Therapy Areas

Since its inception, pharma& has acquired and integrated 10+ medicines, expanding its portfolio across a wide range of therapy areas, with an increasing focus on hematology and oncology treatments.



Our Unique, Integrated Business Model

Our worldwide network of partners, combined with pharma&'s presence in 15 countries with a geographic focus on Europe and the U.S., spans all pharmaceutical functions, making us an integration powerhouse across the development continuum. This includes full value chain capabilities covering the entire product life cycle. **Together, we are the pharma& Group.**




¹ Dewact Labs is a joint venture of pharmaand GmbH and part of the pharma& Group.


² Loba biotech GmbH is a subsidiary of pharmaand GmbH and part of the pharma& Group to support product manufacturing and active pharmaceutical ingredient production.

³ Summit SD is a U.S.-based strategic partnership with a specialty distribution wholesaling company distributing products, founded in the U.S. and committed to continuity of care and uninterrupted access to medicines.

⁴ Heritage Specialty Pharmacy is a U.S.-based strategic partnership with a home-infusion specialty pharmacy that specializes in the treatment of rare and chronic diseases through patient-centric care.

Abbreviations: API - Active Pharmaceutical Ingredient; PV - Pharmacovigilance






Partners

MAIN PARTNERS



SILVER



PARTENERS

